Active	Status	Sponsor type	Region	Phase	Filter
18 Active 5 Inactive 23 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

9 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Barone, Paolo
NCT05357989 / 2022-001542-38: A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD	Completed	3	523	Europe, US	buntanetap/posiphen, Posiphen Tartrate, ANVS401, Placebo	Annovis Bio Inc., TFS Trial Form Support	Parkinson's Disease, Idiopathic	12/23	12/23
ENVISION, NCT05310071 / 2022-001671-14: A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease	Terminated	3	1027	Europe, Canada, Japan, US, RoW	Aducanumab, BIIB037, Aducanumab-avwa, Aduhelm, Placebo	Biogen, Biogen Idec Research Limited	Alzheimer's Disease	08/24	08/24
ORION, NCT06122662: AMX0035 and Progressive Supranuclear Palsy	Active, not recruiting	2/3	110	Europe, US	AMX0035, Placebo	Amylyx Pharmaceuticals Inc.	Progressive Supranuclear Palsy, PSP, Neurodegenerative Diseases, Atypical Parkinsonism	04/26	11/29
ACTIVATE, NCT05819359: Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD	Active, not recruiting	2	237	Europe, Canada, US	BIA 28-6156 10 mg, BIA 28-6156 60 mg, Placebo	Bial R&D Investments, S.A.	Parkinson's Disease	03/26	07/26
Mari, Zoltan
TEMPO-3, NCT04542499 / 2019-002951-40: Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations	Completed	3	507	Europe, US, RoW	Tavapadon, PF-06649751, CVL-751, Placebo	Cerevel Therapeutics, LLC	Parkinson Disease	01/24	02/24
TEMPO-1, NCT04201093 / 2019-002949-38: Fixed-Dose Trial in Early Parkinson's Disease (PD)	Completed	3	522	Europe, Canada, US, RoW	Tavapadon, PF-06649751, CVL-751, Placebo	Cerevel Therapeutics, LLC	Parkinson Disease	06/24	06/24
NCT05251701: Personal KinetiGraph® Clinical Validation Study	Recruiting	N/A	500	US	Personal KinetiGraph® (PKG®) System	Global Kinetics Corporation	Movement Disorders, Parkinson Disease	01/24	01/25
NCT06219629: Parkinson's Disease Progression Study	Recruiting	N/A	70	US		Koneksa Health, Merck Sharp & Dohme LLC, Regeneron Pharmaceuticals	Parkinson Disease	08/25	09/25
Ainscough, Susan
ACTIVATE, NCT05819359: Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD	Active, not recruiting	2	237	Europe, Canada, US	BIA 28-6156 10 mg, BIA 28-6156 60 mg, Placebo	Bial R&D Investments, S.A.	Parkinson's Disease	03/26	07/26
Center, PPMI Call
No trials found
Galasso, Gennaro
No trials found